TIXiMED is developing TIX100, an oral medication that inhibits TXNIP to improve glycemic control in patients with Type 1 and Type 2 diabetes. This novel therapeutic approach addresses the lack of oral treatments for diabetes and aims to reduce excessive glucagon levels while protecting insulin production and preventing complications associated with metabolic dysfunction.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Type 1 diabetes patients require multiple daily insulin injections or infusions to survive, and there are currently no oral medications available to manage the disease. Existing treatments do not address the problem of excessive glucagon levels associated with diabetes, nor do they target the underlying causes of metabolic dysfunction–associated steatotic liver disease (MASLD).
Solution
TIXiMED is developing TIX100, a first-in-class oral therapeutic designed to improve glycemic control in patients with Type 1 and Type 2 diabetes, as well as MASLD. TIX100 inhibits TXNIP (thioredoxin-interacting protein), a key therapeutic target, to address the underlying causes of the disease. By lowering elevated TXNIP levels, TIX100 protects beta cell insulin production and inhibits the excessive secretion of glucagon typically seen in diabetes. Preclinical data suggests TIX100 may also reduce blood lipids and protect against fatty liver.
Target Audience
The primary target audience includes individuals with Type 1 and Type 2 diabetes, as well as those with metabolic dysfunction–associated steatotic liver disease (MASLD).
Features
- Orally administered small molecule drug
- Specifically targets and inhibits TXNIP
- Demonstrated efficacy in animal models of Type 1 and Type 2 diabetes, as well as MASLD
- Does not cause hypoglycemia, fatty liver, hyperlipidemia, or weight gain in preclinical studies
- Favorable pharmacokinetic and safety profile
- Completed Phase 1 single ascending dose clinical study in human subjects